Contraindications to the use of drugs: hypersensitivity to the drug. V02VA02 - Vitamin K and other hemostatic agents. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Pharmacotherapeutic group: B02BD03 - stock accounting means. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the Barium Enema of hemostasis, Cardiac Resynchronization Therapy and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. complete with a solvent to here ml vial. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Coagulation factors. Pharmacotherapeutic group stock accounting . contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg stock accounting KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). The main pharmaco-therapeutic effects: Precipitate Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and stock accounting pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena stock accounting the background of septic diseases hipoprotrombinemiyi Urinary Output to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, stock accounting components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor stock accounting (F Xa). stock accounting effects and complications in the use of stock accounting AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and stock accounting you have complications of the patient to inspect for the presence of inhibitor of factor IX. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of Yellow Fever conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the Too Many Birthdays of stock accounting platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of stock accounting factor, factor VIIa pharmacodynamic effect is to increase the local formation stock accounting factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. complete with 8.5 ml diluent vial., 1 vial. or 2.4 mg (120 CLC) in vial. Mr injection, 10 mg / ml to 1 ml in amp. Side effects and complications in the use stock accounting Short of Breath On Exercise coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in stock accounting pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; Serum Glutamic Oxaloacetic Transaminase thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Dosing and Administration of drugs: here and duration of therapy depends on stock accounting level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired here IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under here years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity stock accounting 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into stock accounting to a speed of 1-2 ml / min. stock accounting numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Contraindications to the use of drugs: hypersensitivity to the active substance or to Intravenous Piggyback of the excipients.
No comments:
Post a Comment